Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Orphan drug sales reach $242bn by 2024, according to EvaluatePharma® Orphan Drug Report 2019
Vantage releases annual analysis of Pharma, Biotech and Medtech performance
EvaluateMedTech Report Launches in Conjunction with The MedTech Conference.
EP Vantage Releases Half-Year Reviews of Pharma & Biotech and Medtech Performance.
Latest growth forecasts show optimism surrounding new therapies coming to market counterbalanced by more stringent pricing policy enforcement.
New Case Studies Highlight Niche Patient Population Identification and Analysis for Enhanced Portfolio Decision-making Using Evaluate’s Epi Analyzer
Fall comes as average cost of developing new drugs totals $4bn over the last 10 years.
Annual Pharma & Biotech World Preview Report to Launch at Bio 2017
Annual "EvaluatePharma Orphan Drug 2017 Report" sees continued growth (CAGR 2017 to 2022: +11.1%) for orphan drugs, approximately double overall prescription…
Falling stock markets, political uncertainty and continued global economic weakness all contributed to a mixed first half for the pharma and medtech industries.
Life science market intelligence firm, Evaluate Ltd today announces that it has been selected as one of 10 companies in the “Ones to Recognise” category in the Sunday…